Tag - IGXT

The United States Patent and Trademark Office has granted a notice of allowance for IntelGenx’s (TSX:IGX; OTCQB:IGXT) U.S. patent application entitled, “Loxapine Film Oral Dosage Form.” The film formulation patent...

IntelGenx (TSX:IGX; OTCQB:IGXT) announced a research collaboration with Per Svenningsson, M.D., Ph.D., of the Karolinska Institute, to plan and conduct a multicentre, randomized, double-blind, placebo-controlled...

IntelGenx (TSX:IGX; OTCQB:IGXT) entered into an exclusive supply agreement for its RIZAPORT product with ARWAN Pharmaceuticals Industries Lebanon for various countries in the Middle East and North Africa, known as the...

IntelGenx (TSX:IGX; OTCQB:IGXT) and the University of Prince Edward Island are collaborating on a research project to assess palatability, owner-perceived acceptability, and ease of administration of IntelGenx’s...

The FDA accepted for review IntelGenx’s (TSX:IGX; OTCQB:IGXT) Class 2 response to a 2020 complete response letter for the company’s 505(b)(2) NDA for RIZAFILM VersaFilm for the treatment of acute migraine. The FDA has...

IntelGenx (TSX:IGX; OTCQB:IGXT) entered into a feasibility study and development agreement with an undisclosed animal health company focused on advancing a VetaFilm-based oral film formulation containing CBD for use in...

IntelGenx (TSX:IGX; OTCQB:IGXT) filed a new provisional patent application with the United States Patent and Trademark Office (USPTO) entitled, “Advanced Oral Film Formulations.” The patent application...

IntelGenx’s (TSX:IGX; OTCQB:IGXT) previously undisclosed development candidate, buprenorphine buccal film, for which an abbreviated new drug application (ANDA) has been filed by Chemo Research through its agent and...

IntelGenx Corp. (TSX:IGX; OTCQB:IGXT) received U.S. Patent No. 11,471,406 from the United States Patent and Trademark Office, with claims for modulating drug absorption in oral film dosage form designed for sublingual...

IntelGenx (TSX:IGX; OTCQB:IGXT) responded to the complete response letter (CRL) for its 505(b)(2) NDA for RIZAPORT VersaFilm received from the FDA in March 2020. “We have been encouraged by our interactions with...